跳至主要内容
临床试验/CTRI/2023/10/058787
CTRI/2023/10/058787尚未招募Unknown

Post Marketing Observational Study PMOS To Evaluate the Safety and Efficacy of HBCR – 011805 Soothing Baby Rub In 0-36 Months Babies.

Himalaya Wellness Company20 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2023年10月26日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
入组人数
500
试验地点
20
主要终点
To evaluate the safety and efficacy of Test Product in study population

研究概览

简要总结

**STUDYOBJECTIVE:**To evaluate the safety and efficacy of soothing babyrub in 0-36 month’s babies with acute cold symptoms.

 **STUDY DESIGN:**An open label, postmarketing observational study.

StudyMethodology:

  1. Parents/LegallyAcceptable Representatives (LARs) of the baby will be provided with the Parent consentdocument and explained about the study in detail.

  2. Babies who fulfil theselection criteria will be enrolled into the study after written parent consent.

  3. The subject’s parent/LAR will be provided with The Himalaya Soothing Baby Rub , and they will beinstructed on the use the product by the study doctor/ coordinator.

  4. Assessments will beperformed on Day 1/baseline and at the end of the study visit at symptomsresolution or day 7 whichever is earlier as per the schedule of events.

  5. If subjects score forLocal intolerance is scored 1= Mild, 2=Moderate, 3=Severe, then the undesirableeffect page to be completed.

  6. All undesirableeffects to be followed up till the event is stabilized or 7days whichever isearlier

Studyduration: Thisstudy is planned till symptoms resolution or day 7 (+ 1 day) whichever isearlier.

Numberof Subjects: 500 subjects will be enrolled.

**StudySite:**Thestudy will be conducted at 20 sites.

Directions to Use: Take a small amount of Himalaya Soothing BabyRub onto your fingertips and gently apply on your baby’s chest, neck, and back.Use as and whenever required

研究设计

研究类型
Observational

入排标准

年龄范围
0.00 Day(s) 至 36.00 Month(s)(—)
性别
All

入选标准

  • •1.Subjects in the age group of 0 to 36 months.
  • •2.Subject with acute cold symptoms having signs and symptoms as listed below a.Nasal congestion/blockage, b.Itchy nose, c.Sneezing, d.Runny nose.
  • •3.Subjects in general good health as determined from a recent medical history and physical examination.
  • •4.Subjects mother/legal representative willing to give a voluntary written parent consent and agree to comply with the study protocol.

排除标准

  • •1.Subjects with a known history or present condition of allergic response to any other vapo rub, balm, or its components or ingredients as in the test product.
  • •2.Subjects having history or present condition of respiratory diseases, or any significant allergies.
  • •3.Subjects requiring medical treatment for the indicated symptoms.
  • •4.Chronic illness which may influence the cutaneous assessment.
  • •5.Subjects who have participated in a similar clinical investigation in the past four weeks.

结局指标

主要结局

To evaluate the safety and efficacy of Test Product in study population

时间窗: 7 days.

次要结局

  • NA(NA)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (20)

Loading locations...

相似试验